Advantages of Metabolomics-Based Multivariate Machine Learning to Predict Disease Severity: Example of COVID.

Journal: International journal of molecular sciences
Published Date:

Abstract

The COVID-19 outbreak caused saturations of hospitals, highlighting the importance of early patient triage to optimize resource prioritization. Herein, our objective was to test if high definition metabolomics, combined with ML, can improve prognostication and triage performance over standard clinical parameters using COVID infection as an example. Using high resolution mass spectrometry, we obtained metabolomics profiles of patients and combined them with clinical parameters to design machine learning (ML) algorithms predicting severity (herein determined as the need for mechanical ventilation during patient care). A total of 64 PCR-positive COVID patients at the Poitiers CHU were recruited. Clinical and metabolomics investigations were conducted 8 days after the onset of symptoms. We show that standard clinical parameters could predict severity with good performance (AUC of the ROC curve: 0.85), using SpO2, first respiratory rate, Horowitz quotient and age as the most important variables. However, the performance of the prediction was substantially improved by the use of metabolomics (AUC = 0.92). Our small-scale study demonstrates that metabolomics can improve the performance of diagnosis and prognosis algorithms, and thus be a key player in the future discovery of new biological signals. This technique is easily deployable in the clinic, and combined with machine learning, it can help design the mathematical models needed to advance towards personalized medicine.

Authors

  • Maryne Lepoittevin
    Inserm Unit Ischémie Reperfusion, Métabolisme et Inflammation Stérile en Transplantation (IRMETIST), UMR U1313, F-86073 Poitiers, France.
  • Quentin Blancart Remaury
    UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), University of Poitiers, 4 rue Michel-Brunet, TSA 51106, F-86073 Poitiers cedex 9, France.
  • Nicolas Lévêque
    LITEC, CHU de Poitiers, Laboratoire de Virologie et Mycobactériologie, Université de Poitiers, 2 r Milétrie, F-86000 Poitiers, France.
  • Arnaud W Thille
    Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Poitiers, France.
  • Thomas Brunet
    Geriatric Medicine Department, CHU Poitiers, F-86021 Poitiers, France.
  • Karine Salaun
    Intensive Care Medicine Department, CHU Poitiers, F-86021 Poitiers, France.
  • Mélanie Catroux
    Internal Medicine and Infectious Disease Department, CHU Poitiers, F-86021 Poitiers, France.
  • Luc Pellerin
    Inserm Unit Ischémie Reperfusion, Métabolisme et Inflammation Stérile en Transplantation (IRMETIST), UMR U1313, F-86073 Poitiers, France.
  • Thierry Hauet
    Department of Pharmacology, Poitiers University Hospital, Poitiers, France.
  • Raphael Thuillier
    Inserm Unit Ischémie Reperfusion, Métabolisme et Inflammation Stérile en Transplantation (IRMETIST), UMR U1313, F-86073 Poitiers, France.